<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Public Datasets | AMRcloud</title>
    <link>https://amrcloud.net/en/project/</link>
      <atom:link href="https://amrcloud.net/en/project/index.xml" rel="self" type="application/rss+xml" />
    <description>Public Datasets</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>AMRcloud © 2024</copyright><lastBuildDate>Sat, 23 Sep 2023 09:00:00 +0000</lastBuildDate>
    <image>
      <url>https://amrcloud.net/img/amr-cloud-logo-text.png</url>
      <title>Public Datasets</title>
      <link>https://amrcloud.net/en/project/</link>
    </image>
    
    <item>
      <title>Research project: Veterinary monitoring and Risk Analysis of Zoonotic Bacteria Antimicrobial Resistance.</title>
      <link>https://amrcloud.net/en/project/vgnki/</link>
      <pubDate>Sat, 23 Sep 2023 09:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/vgnki/</guid>
      <description>&lt;h3 id=&#34;russian-state-center-for-quality-and-standardization-of-veterinary-drugs-and-feed&#34;&gt;Russian State Center for Quality and Standardization of Veterinary Drugs and Feed&lt;/h3&gt;
&lt;p&gt;Research Institute of the Federal Service for Veterinary and Phytosanitary Surveillance (ROSSELKHOZNADZOR).&lt;/p&gt;
&lt;p&gt;OIE collaborating Center on Food Safety, Diagnosis and Control of Animal Diseases in Eastern Europe, Central Asia and Transcaucasia.&lt;/p&gt;
&lt;p&gt;Main activities of VGNKI are ensuring veterinary drugs quality, food of animal origin and feed safety, certification and registration of veterinary drugs, feed and feed additives, including GMO-containing.&lt;/p&gt;
&lt;h3 id=&#34;abstract&#34;&gt;Abstract:&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Dаta for 2017-2023 years&lt;/li&gt;
&lt;li&gt;4251 isolates
&lt;ul&gt;
&lt;li&gt;&lt;em&gt;Esherichia coli&lt;/em&gt; – 1505,&lt;/li&gt;
&lt;li&gt;&lt;em&gt;Enterococcus spp.&lt;/em&gt; (&lt;em&gt;E.faecalis&lt;/em&gt;, &lt;em&gt;E.faecium&lt;/em&gt;, etc.) – 1554,&lt;/li&gt;
&lt;li&gt;&lt;em&gt;Salmonella enterica&lt;/em&gt; – 647,&lt;/li&gt;
&lt;li&gt;&lt;em&gt;Campylobacter spp.&lt;/em&gt; (&lt;em&gt;C.jejuni&lt;/em&gt;, &lt;em&gt;C.coli&lt;/em&gt;, etc.) – 161,&lt;/li&gt;
&lt;li&gt;&lt;em&gt;Staphylococcus spp.&lt;/em&gt; (&lt;em&gt;S.aureus&lt;/em&gt;, &lt;em&gt;S.haemolyticus&lt;/em&gt;, etc.) – 193&lt;/li&gt;
&lt;li&gt;&lt;em&gt;Listeria monocytogenes&lt;/em&gt; - 191&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;Isolates taken from poultry (chicken, turkeys, ducks, geese), cows, pigs, sheep, goats, horses, rabbits, fish.&lt;/li&gt;
&lt;li&gt;Geographic coverage – 37 regions of Russia from Kaliningrad to the Far East, Belarus, Iran, Turkey.&lt;/li&gt;
&lt;li&gt;Types of samples: animal biomaterial, internal environment of the enterprise (flushes from equipment, bedding, etc.), food products, incoming material (feed, water), soil at the grazing site.&lt;/li&gt;
&lt;li&gt;30 antimicrobials from 16 classes: amoxicillin, ampicillin (penicillins), azithromycin (azalides), cefotaxime, ceftaroline, ceftiofur (cephalosporins),chloramphenicol, florfenicol (amphenicols), ciprofloxacin, enrofloxacin, levofloxacin, marbofloxacin, moxifloxacin (fluoroquinolones), clindamycin (lincosamides), colistin, bacitracin (polypeptides), doxycycline, tetracycline (tetracyclines), erythromycin (macrolides), gentamicin, spectinomycin, streptomycin (aminoglycosides), meropenem (carbapenems), rifampicin (anzamycins), sulfadiazine, sulfamethoxazole (sulfonamides), trimethoprim (diaminopyrimidines), trimethoprim/sulfamethoxazole combination, vancomycin (glycopeptides), virginiamycin (streptograms).&lt;/li&gt;
&lt;li&gt;Antimicrobial susceptibility testing method: Broth microdilution.&lt;/li&gt;
&lt;li&gt;Interpretation according to EUCAST2023 clinical breakpoints and EUCAST ECOFFs.&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;data&#34;&gt;Data:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;Bogomazova A.N.&lt;/li&gt;
&lt;li&gt;Gergel M.A.&lt;/li&gt;
&lt;li&gt;Gordeeva V.D.&lt;/li&gt;
&lt;li&gt;Grizuk V.A.&lt;/li&gt;
&lt;li&gt;Ivanova O.E.&lt;/li&gt;
&lt;li&gt;Karabanov S.Yu.&lt;/li&gt;
&lt;li&gt;Komarov A.A.&lt;/li&gt;
&lt;li&gt;Krylova E.V.&lt;/li&gt;
&lt;li&gt;Kulikovsky A.V.&lt;/li&gt;
&lt;li&gt;Lenyov S.V.&lt;/li&gt;
&lt;li&gt;Lobova P.A.&lt;/li&gt;
&lt;li&gt;Makarov D.A.&lt;/li&gt;
&lt;li&gt;Pleskacheva M.A.&lt;/li&gt;
&lt;li&gt;Pobolelova Yu.I.&lt;/li&gt;
&lt;li&gt;Pomazkova A.V.&lt;/li&gt;
&lt;li&gt;Prasolova O.V.&lt;/li&gt;
&lt;li&gt;Rusakov S.V.&lt;/li&gt;
&lt;li&gt;Soltynskaya I.V.&lt;/li&gt;
&lt;li&gt;Sukhoedova A.V.&lt;/li&gt;
&lt;li&gt;Yatsentyuk S.P.&lt;/li&gt;
&lt;/ul&gt;
&lt;blockquote&gt;
&lt;p&gt;You can leave you questions and comments by e-mail: 
&lt;a href=&#34;mailto:phorez@yandex.ru&#34;&gt;phorez@yandex.ru&lt;/a&gt; (Makarov D.A.)&lt;/p&gt;
&lt;/blockquote&gt;
</description>
    </item>
    
    <item>
      <title>The main gram-negative bacterial pathogens recovered from cystic fibrosis patients</title>
      <link>https://amrcloud.net/en/project/muco-v/</link>
      <pubDate>Tue, 14 Jun 2022 09:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/muco-v/</guid>
      <description>&lt;h3 id=&#34;organisers&#34;&gt;Organisers&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Pirogov Russian National Research Medical University&lt;/li&gt;
&lt;li&gt;Samara State Medical University&lt;/li&gt;
&lt;li&gt;Filatov Municipal Clinical Hospital&lt;/li&gt;
&lt;li&gt;Morozov City Children’s Clinical Hospital&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;abstract&#34;&gt;Abstract&lt;/h3&gt;
&lt;p&gt;The main gram-negative cystic fibrosis bacterial pathogens include &lt;em&gt;Pseudomonas aeruginosa&lt;/em&gt;, &lt;em&gt;Achromobacter spp.&lt;/em&gt;, &lt;em&gt;Burkholderia cepacia complex&lt;/em&gt; and &lt;em&gt;Stenotrophomonas maltophilia&lt;/em&gt;. In this project, the results of antibiotic susceptibility testing of the main gram-negative cystic fibrosis bacterial pathogens recovered from cystic fibrosis patients in Russia are presented.&lt;/p&gt;
&lt;h3 id=&#34;bacterial-isolates&#34;&gt;Bacterial isolates&lt;/h3&gt;
&lt;p&gt;In January – February 2020, respiratory tract samples from 170 cystic fibrosis patients (5% of all cystic fibrosis patients in Russia) from 42 regions were analyzed. The detected main gram-negative cystic fibrosis bacterial pathogens (&lt;em&gt;P. aeruginosa&lt;/em&gt;, &lt;em&gt;Achromobacter spp.&lt;/em&gt;, &lt;em&gt;Burkholderia cepacia complex&lt;/em&gt; and &lt;em&gt;S. maltophilia&lt;/em&gt;) were studied.&lt;/p&gt;
&lt;h3 id=&#34;antibiotic-susceptibility-testing&#34;&gt;Antibiotic susceptibility testing&lt;/h3&gt;
&lt;p&gt;Minimum inhibitory concentrations of antibacterial agents were determined using broth microdilution method. The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI, 2020) criteria.&lt;/p&gt;
&lt;h3 id=&#34;study-group&#34;&gt;Study group&lt;/h3&gt;
&lt;p&gt;Bocharova Yu.A., Savinova T.A., Lyamin A.V., Kondratenko O.V., Fedorova N.I., Semykin S.Yu., Polikarpova S.V., Zhilina S.V., Chaplin A.V., Korostin D.O., Mayansky N.A., Chebotar I.V.&lt;/p&gt;
&lt;h3 id=&#34;funding&#34;&gt;Funding&lt;/h3&gt;
&lt;p&gt;The study was supported by the Russian Science Foundation (Project ID 20-15-00235).&lt;/p&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Contact&lt;/h3&gt;
    &lt;h5&gt;Yuliya Bocharova&lt;/h5&gt;
    &lt;p&gt;Senior researcher, laboratory of molecular microbiology,&lt;br&gt;Pirogov Russian National Research Medical University&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;mailto:ivrin7@gmail.com&#34; target=&#34;_blank&#34;&gt;ivrin7@gmail.com&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;rnimu.png&#34; style=&#34;width: 300px&#34; alt=&#34;Pirogov Russian National Research Medical University&#34;&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>DeMaRes Study</title>
      <link>https://amrcloud.net/en/project/demares/</link>
      <pubDate>Thu, 08 Apr 2021 09:00:00 +0300</pubDate>
      <guid>https://amrcloud.net/en/project/demares/</guid>
      <description>&lt;h3 id=&#34;organizers&#34;&gt;Organizers&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)&lt;/li&gt;
&lt;li&gt;Institute of Antimicrobial Chemotherapy (IAC), Smolensk State Medical University&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;annotation&#34;&gt;Annotation&lt;/h3&gt;
&lt;p&gt;&lt;em&gt;Mycoplasma genitalium&lt;/em&gt; is a common sexually transmitted pathogen in men and women.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; is an ‘atypical’ bacterial pathogen that causes lower respiratory infections, including pneumonia and tracheobronchitis, and less commonly, upper respiratory tract infections.&lt;/p&gt;
&lt;p&gt;This dataset presents the results of longitudinal surveillance study of mutational resistance to macrolides (mutations in domain V of the 23S rRNA gene) and fluoroquinolones (mutations in quinolone resistance-determining regions (QRDRs) of &lt;em&gt;gyrA&lt;/em&gt; and &lt;em&gt;parC&lt;/em&gt; genes) of &lt;em&gt;M. genitalium&lt;/em&gt; and &lt;em&gt;M. pneumoniae&lt;/em&gt;.&lt;/p&gt;
&lt;h3 id=&#34;sources-of-clinical-samples&#34;&gt;Sources of clinical samples&lt;/h3&gt;
&lt;p&gt;&lt;em&gt;M. genitalium&lt;/em&gt; PCR-positive urogenital samples (n=873) were collected in five regions of Russia: Moscow, Nizhny Novgorod, Saratov, Smolensk, and Tula, in 2009-2019.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;M. pneumoniae&lt;/em&gt; PCR-positive samples (n=1480) were collected in twelve regions of Russia: Bryansk, Khabarovsk, Krasnoyarsk, Mari El Republic, Moscow, Moscow Region, Nizhny Novgorod, Penza, Smolensk, Sverdlovsk, Tula, and Yaroslavl, in 2006-2020.&lt;/p&gt;
&lt;p&gt;All samples were collected as part of routine diagnostics for genitourinary and respiratory infections and were non-duplicate (represented individual patients/cases of infection). PCR-positive samples were referred to the IAC central laboratory for analysis of antibiotic resistance-associated mutations&lt;/p&gt;
&lt;h3 id=&#34;detection-of-macrolide-and-fluoroquinolone-resistance-associated-mutations&#34;&gt;Detection of macrolide and fluoroquinolone resistance-associated mutations&lt;/h3&gt;
&lt;p&gt;Single nucleotide substitutions at positions 2058-2062 and 2611 of domain V of the 23S rRNA and mutations conferring amino acid (aa) changes at QRDR regions of ParC (aa positions 79-84) and GyrA (aa positions 83-87) were detected by means of probe-based real-time PCR assays  and were confirmed by independent PCR amplification and Sanger sequencing of the corresponding gene fragments [2-4].&lt;/p&gt;
&lt;p&gt;The data on the types of mutations detected is presented under the ‘Markers’ section of the website.&lt;/p&gt;
&lt;h3 id=&#34;study-group&#34;&gt;Study group:&lt;/h3&gt;
&lt;h4 id=&#34;iac-laboratory&#34;&gt;IAC laboratory:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;Edelstein I.A.,&lt;/li&gt;
&lt;li&gt;Romanov A.V.,&lt;/li&gt;
&lt;li&gt;Edelstein M.V.,&lt;/li&gt;
&lt;li&gt;Kuzmenkov A.Yu.,&lt;/li&gt;
&lt;li&gt;Kozlov R.S.&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;participating-centers&#34;&gt;Participating centers:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;Aksyutina G.V. (Bryansk)&lt;/li&gt;
&lt;li&gt;Alyabyeva N.A. (Moscow)&lt;/li&gt;
&lt;li&gt;Borisov I.V. (Saratov)&lt;/li&gt;
&lt;li&gt;Groshenkova E.V. (Yaroslavl)&lt;/li&gt;
&lt;li&gt;Gushin A.E. (Moscow)&lt;/li&gt;
&lt;li&gt;Ershova M.G. (Yaroslavl)&lt;/li&gt;
&lt;li&gt;Enikeeva F.S. (Penza)&lt;/li&gt;
&lt;li&gt;Zaitsev A.A. (Moscow)&lt;/li&gt;
&lt;li&gt;Zubareva L.M. (Smolensk)&lt;/li&gt;
&lt;li&gt;Ignatkova A.S. (Tula)&lt;/li&gt;
&lt;li&gt;Ivanova O.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Ivanova I.A. (Yoshkar-Ola)&lt;/li&gt;
&lt;li&gt;Kolesnikova E.A. (Nizhny Novgorod)&lt;/li&gt;
&lt;li&gt;Majarova O.A. (Minsk, Belarus)&lt;/li&gt;
&lt;li&gt;Novikova O.P. (Tula)&lt;/li&gt;
&lt;li&gt;Olenkova O.M. (Ekaterinburg)&lt;/li&gt;
&lt;li&gt;Pleskachevskaya T.A. (Smolensk)&lt;/li&gt;
&lt;li&gt;Protasova I.N. (Krasnoyarsk)&lt;/li&gt;
&lt;li&gt;Rudneva N.S. (Tula)&lt;/li&gt;
&lt;li&gt;Semenova O.L. (Bryansk)&lt;/li&gt;
&lt;li&gt;Tsykhanovskaya O.A. (Tver)&lt;/li&gt;
&lt;li&gt;Yatsyshina S.B. (Moscow)&lt;/li&gt;
&lt;/ul&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Coordinator&lt;/h3&gt;
    &lt;h5&gt;Inna Edelstein, PhD&lt;/h5&gt;
    &lt;p&gt;Head, Laboratory of Molecular Diagnostics, IAC&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;mailto:inna.edelstein@antibiotic.ru &#34; target=&#34;_blank&#34;&gt;inna.edelstein@antibiotic.ru&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;iac.png&#34; style=&#34;width: 200px&#34; alt=&#34;НИИ антимикробной химиотерапии ФГБОУ ВО «СГМУ» Минздрава России&#34;&gt;
&lt;/div&gt;
&lt;h3 id=&#34;publications&#34;&gt;Publications&lt;/h3&gt;
&lt;ol&gt;
&lt;li&gt;Edelstein I.A. &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; – modern data on the structure, molecular biology and epidemiology of the pathogen. Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):332-349 
&lt;a href=&#34;https://doi.org/10.36488/cmac.2023.4.332-349&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.36488/cmac.2023.4.332-349&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Edelstein I.A., Guschin A.E., Romanov A.V., Negasheva E.S., Kozlov R.S. Genetic Determinants of Macrolide and Fluoroquinolone Resistance in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; and Their Prevalence in Moscow, Russia. Pathogens. 2023; 12(3):496. 
&lt;a href=&#34;https://doi.org/10.3390/pathogens12030496&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.3390/pathogens12030496&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Edelstein I.A., Romanov A.V., Kozlov R.S. Development of a Real-Time PCR Assay for Detection of Macrolide Resistance Mutations in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; and Its Application for Epidemiological Surveillance in Russia. Microbial Drug Resistance.Mar 2023.69-77. 
&lt;a href=&#34;https://doi.org/10.1089/mdr.2022.0131&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.1089/mdr.2022.0131&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Edelstein, I.A.; Ivanova, O.V.; Romashov, O.I.; Kozlov, R.S. Course of Lower Respiratory Tract Infection in Young People Treated at the Military Hospital of Smolensk Garrison with Detected Mycoplasma pneumoniae Carrying a Macrolide-Resistant Mutation in 23S rRNA Gene. Pathogens 2023, 12, 103. 
&lt;a href=&#34;https://doi.org/10.3390/pathogens12010103&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.3390/pathogens12010103&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Edelstein I.A., Rudneva N.S.,  Romanov A.V., Zubareva L.M.,  Kuzmenkov A.Yu., Kolesnikova E.A.,  Trushin I.V., Borisov I.V., Sukhanova L.N., Akhmedova A.M., Novikova O.P.,  Kozlov R.S. Monitoring of macrolide resistanceassociated mutations in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; in Russia. Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):52-60. 
&lt;a href=&#34;https://doi.org/10.36488/cmac.2022.1.52-60&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.36488/cmac.2022.1.52-60&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Romanov A.V., Kozlov R.S., Edelstein I.A., Edelstein M.V. Method of detection of fluoroquinolone resistance-associated mutations genes parC and gyrA QRDR in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt;. Patent # RU 2778666 C1, 22.08.2022. 
&lt;a href=&#34;https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&amp;amp;DocNumber=2778666&amp;amp;TypeFile=html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ref&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Ivanova O.V., Edelstein I.A., Romashov O.I., Kozlov R.S. Effect of 23S rRNA gene mutations in Mycoplasma pneumoniae on severity of community acquired pneumonia in young adult patients treated at the Smolensk military hospital. Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(4):306-312. 
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2020/4/cmac-2020-t22-n4-p306/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.36488/cmac.2020.4.306-312&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Zubareva L.M., Edelstein I.A., Rudneva N.S., Romanov A.V., Vlasova T.A., Lavrinenkova Yu.V., Sukhanova L.N., Ahmedova A.M., Kuzmenkov A.Yu., Trushin I.V., Evstafev V.V. The rates of mutations associated with macrolide resistance in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; among patients with non-gonococcal sexually transmitted infections in Smolensk and Tula. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(4):330-339. 
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2019/4/cmac-2019-t21-n4-p330/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.36488/cmac.2019.4.330-339&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Zubareva L.M., Edelstein I.A., Romanov A.V., Evstafev V.V., Kozlov R.S. Clinical case of failure of josamycin in a patient with urethritis caused by &lt;em&gt;Mycoplasma genitalium&lt;/em&gt;. Vestnik Dermatologii i Venerologii. 2018;94(4):55-59. 
&lt;a href=&#34;https://vestnikdv.ru/jour/article/view/424&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.25208/0042-4609-2018-94-4-55-59&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;​Edelstein I.A., Edelstein M.V., Romanov A.V., Zaitsev A.A., Rakovskaya I.V., Barkhatova O.I., Antipushina D.N., Kozlov R.S. Four cases of resistance mutations in 23S rRNA gene in &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; isolated from the hospitalized military personnel. Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(3):248-253. 
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2017/3/cmac-2017-t19-n3-p248/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ref&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Romanov A.V., Kozlov R.S., Edelstein I.A., Edelstein M.V. Method of detection of macrolide resistance-associated mutations in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; and &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt;. Patent # RU 2646123 C1, 01.03.2018. 
&lt;a href=&#34;https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&amp;amp;DocNumber=2646123&amp;amp;TypeFile=html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ref&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Edelstein I.A., Edelstein M.V., Romanov A.V., Ratchina S.A., Yatsyshina S.B., Rakovskaja I.V., Kozlov R.S. Detection of macrolide-resistance mutations in 23S rRNA gene of &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; using a novel real-time PCR assay. Pacific Medical Journal. 2015; (1):63-66. 
&lt;a href=&#34;https://www.tmj-vgmu.ru/jour/article/view/606?locale=en_US&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ref&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;Shipitsyna E, Rumyantseva T, Golparian D, Khayrullina G, Lagos AC, Edelstein I, Joers K, Jensen JS, Savicheva A, Rudneva N, Sukhanova L, Kozlov R, Guschin A, Unemo M. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in &lt;em&gt;Mycoplasma genitalium&lt;/em&gt; in five cities in Russia and Estonia. PLoS One. 2017. Apr 13; 12(4). 
&lt;a href=&#34;https://doi.org/10.1371/journal.pone.0175763&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 1371/journal.pone.0175763&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Edelstein I., Rachina S., Touati A., Kozlov R., Henin N., Bébéar C., Pereyre S. &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; Monoclonal P1 Type 2c, Outbreak, Russia, 2013. Emerging Infectious Diseases. Vol. 22, No. 2, February 2016. 
&lt;a href=&#34;https://doi.org/10.3201/eid2202.151349&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;DOI: 10.3201/eid2202.151349&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;Bobylev A.A., Rachina S.A., Eidelshtein I.A., Kozlov R.S., German S.V., Pogodin A.G. Outbreak of &lt;em&gt;Mycoplasma pneumoniae&lt;/em&gt; infection at Smolensk region. PULMONOLOGIYA. 2013;(5):97-100. (In Russ.) 
&lt;a href=&#34;https://journal.pulmonology.ru/pulm/article/view/288?locale=en_US&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ref&lt;/a&gt;&lt;/li&gt;
&lt;/ol&gt;
</description>
    </item>
    
    <item>
      <title>DARMIS 2009-2011 &amp; 2017-2018</title>
      <link>https://amrcloud.net/en/project/darmis/</link>
      <pubDate>Sun, 14 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/darmis/</guid>
      <description>&lt;h3 id=&#34;organisers&#34;&gt;Organisers&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)&lt;/li&gt;
&lt;li&gt;Russian Society of Urologists&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;annotation&#34;&gt;Annotation&lt;/h3&gt;
&lt;p&gt;This dataset presents the data on antibiotic resistance of community-acquired uropathogens isolated from midstream urine samples of:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;adults with symptomatic UTI (cystitis, pyelonephritis);&lt;/li&gt;
&lt;li&gt;children and adolescents under 18 years with symptomatic UTI (cystitis, pyelonephritis);&lt;/li&gt;
&lt;li&gt;pregnant women with symptomatic UTI (cystitis and pyelonephritis) and asymptomatic bacteriuria.&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;the-study-was-conducted-in-two-periods&#34;&gt;The study was conducted in two periods:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;DARMIS 2009-2011: &lt;strong&gt;28 centers, 20 cities&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Russia&lt;/strong&gt;: Voronezh, Yekaterinburg, Irkutsk, Kazan, Krasnodar, Moscow, Omsk, Rostov-on-Don, Samara, St. Petersburg, Seversk, Smolensk, Surgut, Tomsk, Tyumen, Ufa, Chelyabinsk, Yakutsk;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Belarus&lt;/strong&gt;: Gomel;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Kazakhstan&lt;/strong&gt;: Karaganda.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;DARMIS 2017-2018: &lt;strong&gt;34 centers, 26 cities&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Russia&lt;/strong&gt;: Bratsk, Voronezh, Yekaterinburg, Irkutsk, Yoshkar-Ola, Kazan, Kirov, Krasnodar, Nizhnevartovsk, Novokuznetsk, Novosibirsk, Omsk, Rostov-on-Don, Samara, St. Petersburg, Seversk, Smolensk, Surgut, Tolyatti, Tomsk, Ulyanovsk, Chelyabinsk, Yakutsk, Yaroslavl;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Belarus&lt;/strong&gt;: Gomel;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Kazakhstan&lt;/strong&gt;: Karaganda.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;antibiotic-susceptibility-testing&#34;&gt;Antibiotic Susceptibility Testing&lt;/h4&gt;
&lt;p&gt;Minimum inhibitory concentrations (MICs) of antibiotics were determined by reference broth microdilution method (BMD) in Mueller-Hinton broth according to ISO 20776-1:2006 at the Central Laboratory of the Institute of Antimicrobial Chemotherapy (IAC), Smolensk State Medical University (SSMU)&lt;/p&gt;
&lt;h4 id=&#34;interpretation-of-mics&#34;&gt;Interpretation of MICs&lt;/h4&gt;
&lt;p&gt;Clinical susceptibility categories were assigned according to the 
&lt;a href=&#34;http://www.eucast.org/clinical_breakpoints/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC Clinical breakpoints v.11.0, 2021&lt;/a&gt;&lt;/p&gt;
&lt;h3 id=&#34;darmis-2009-2011-study-group&#34;&gt;DARMIS 2009-2011 Study Group&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Agapova E.D. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Ankirskaya A.S. (Moscow)&lt;/li&gt;
&lt;li&gt;Elokhina E.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Galeeva O.P. (Kazan)&lt;/li&gt;
&lt;li&gt;Gudkova L.V. (Tomsk)&lt;/li&gt;
&lt;li&gt;Gumenetskiy D.V. (Chelyabinsk)&lt;/li&gt;
&lt;li&gt;Khasanova S.G. (Ufa)&lt;/li&gt;
&lt;li&gt;Khokhlyavina R.M. (Tyumen)&lt;/li&gt;
&lt;li&gt;Kogan M.I. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Kozlova L.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Lavrinenko A.V. (Karaganda, Kazakhstan)&lt;/li&gt;
&lt;li&gt;Loginov Yu.A. (Smolensk)&lt;/li&gt;
&lt;li&gt;Malev I.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Morozov M.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Moskvitina E.N. (Seversk)&lt;/li&gt;
&lt;li&gt;Multykh I.G. (Krasnodar)&lt;/li&gt;
&lt;li&gt;Naboka Yu.L. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Nastausheva T.L. (Voronezh)&lt;/li&gt;
&lt;li&gt;Nikolskaya I.G. (Moscow)&lt;/li&gt;
&lt;li&gt;Ortenberg E.A. (Tyumen)&lt;/li&gt;
&lt;li&gt;Oskina E.A. (Samara)&lt;/li&gt;
&lt;li&gt;Palagin I.S. (Smolensk)&lt;/li&gt;
&lt;li&gt;Perevalova E.Yu. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Polukhina O.V. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Rozanova S.M. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Safina A.I. (Kazan)&lt;/li&gt;
&lt;li&gt;Savicheva A.M. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Sekhin S.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Skalskiy S.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Tapalskiy D.V. (Gomel, Belarus)&lt;/li&gt;
&lt;li&gt;Tatarinova O.V. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Trapeznikova B.V. (Surgut)&lt;/li&gt;
&lt;li&gt;Valiullina I.R. (Kazan)&lt;/li&gt;
&lt;li&gt;Zhestkov A.V. (Samara)&lt;/li&gt;
&lt;li&gt;Zulkarneev R.Kh. (Ufa)&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;darmis-2017-2018-study-group&#34;&gt;DARMIS 2017-2018 Study Group&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Amineva P.G. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Becker G.G. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Bulkin A.N. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Bykonya S.A. (Tomsk)&lt;/li&gt;
&lt;li&gt;Chastoedova A.N. (Kirov)&lt;/li&gt;
&lt;li&gt;Domanskaya O.V. (Novokuznetsk)&lt;/li&gt;
&lt;li&gt;Elokhina E.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Ershova M.G. (Yaroslavl)&lt;/li&gt;
&lt;li&gt;Ivanova I.A. (Yoshkar-Ola)&lt;/li&gt;
&lt;li&gt;Khaidarshina N.E. (Chelyabinsk)&lt;/li&gt;
&lt;li&gt;Khusnutdinova T.A. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Kogan M.I. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Kulchavenya E.V. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Lavrinenko A.V. (Karaganda, Kazakhstan)&lt;/li&gt;
&lt;li&gt;Lyamin A.V. (Samara)&lt;/li&gt;
&lt;li&gt;Malev I.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Malyavin A.I. (Ulyanovsk)&lt;/li&gt;
&lt;li&gt;Martyanova N.M. (Tolyatti)&lt;/li&gt;
&lt;li&gt;Moskvitina E.N. (Seversk)&lt;/li&gt;
&lt;li&gt;Mutin M.Yu. (Bratsk)&lt;/li&gt;
&lt;li&gt;Naboka Yu.L. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Nikiforovskaya N.N. (Smolensk)&lt;/li&gt;
&lt;li&gt;Palagin I.S. (Smolensk)&lt;/li&gt;
&lt;li&gt;Plugin P.S. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Popova L.D. (Omsk)&lt;/li&gt;
&lt;li&gt;Portnyagina U.S. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Shamaeva S.Kh. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Shipitsyna E.V. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Shirokova T.M. (Kirov)&lt;/li&gt;
&lt;li&gt;Sidorova R.K. (Ulyanovsk)&lt;/li&gt;
&lt;li&gt;Strebkova V.V. (Voronezh)&lt;/li&gt;
&lt;li&gt;Sukhoreva M.V. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Tapalsky D.V. (Gomel, Belarus)&lt;/li&gt;
&lt;li&gt;Valiullina I.R. (Kazan)&lt;/li&gt;
&lt;li&gt;Varganova A.N. (Surgut)&lt;/li&gt;
&lt;li&gt;Varibrus E.V. (Krasnodar)&lt;/li&gt;
&lt;li&gt;Vasilyeva I.R. (Nizhnevartovsk)&lt;/li&gt;
&lt;li&gt;Vetokhina A.V. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Volkovskaya I.V. (Tomsk)&lt;/li&gt;
&lt;li&gt;Zhestkov A.V. (Samara)&lt;/li&gt;
&lt;/ul&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Coordinator&lt;/h3&gt;
    &lt;h5&gt;Ivan S. Palagin&lt;/h5&gt;
    &lt;p&gt;Research fellow&lt;/p&gt;
    &lt;p&gt;Institute of Antimicrobial Chemotherapy (IAC),&lt;br&gt;Smolensk State Medical University (SSMU)&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;mailto:ivan.palagin@gmail.com&#34; target=&#34;_blank&#34;&gt;ivan.palagin@gmail.com&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;iac.png&#34; alt=&#34;Institute of Antimicrobial Chemotherapy&#34;&gt;
&lt;/div&gt;
&lt;h3 id=&#34;publications&#34;&gt;Publications&lt;/h3&gt;
&lt;ol&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, T.S. Perepanova, R.S. Kozlov, “DARMIS-2018” Study Group. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: results of the international multicenter study “DARMIS-2018”. Urology 2020; 1: 19-31.&lt;br/&gt;
&lt;a href=&#34;https://dx.doi.org/10.18565/urology.2020.1.19-31&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;ai ai-doi&#34;&gt;&lt;/i&gt; 10.18565/urology.2020.1.19-31&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, T.S. Perepanova, R.S. Kozlov, “DARMIS-2018” Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. KMAKH 2019; 21 (2): 134-146.&lt;br/&gt;
&lt;a href=&#34;https://doi.org/10.36488/cmac.2019.2.134-146&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;ai ai-doi&#34;&gt;&lt;/i&gt; 10.36488/cmac.2019.2.134-146&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, A.V. Grinev, T.S. Perepanova, R.S. Kozlov, DARMIS Study Group. Complicated community-acquired urinary tract infections in adult patients in Russia. KMAKH 2014; 16 (1): 39-56. &lt;br/&gt;
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2014/1/cmac-2014-t16-n1-p039/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cmac-journal.ru&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, A.N. Shevelev, A.V. Grinev, T.S. Perepanova, R.S. Kozlov, “DARMIS” Study Group. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia: DARMIS Study (2010-2011). KMAKH 2012; 14 (4): 280-302.&lt;br/&gt;
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2012/4/cmac-2012-t14-n4-p280/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cmac-journal.ru&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;T.S. Perepanova, R.S. Kozlov, A.V. Dekhnich, I.S. Palagin, A.N. Shevelev, E.M. Volkova, D.K. Egamberdiev. Choice of antimicrobial drugs in urinary infections. Urology 2012; 2: 4-8.&lt;br/&gt;
&lt;a href=&#34;https://cyberleninka.ru/article/n/empiricheskiy-vybor-antimikrobnyh-preparatov-pri-neoslozhnennoy-infektsii-nizhnih-mochevyh-putey-issledovanie-rezistentnosti&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cyberleninka.ru&lt;/a&gt;&lt;/li&gt;
&lt;/ol&gt;
</description>
    </item>
    
    <item>
      <title>&lt;em&gt;Acinetobacter baumannii&lt;/em&gt; genetic diversity, susceptibility to antibiotics and lytic phages</title>
      <link>https://amrcloud.net/en/project/abphage/</link>
      <pubDate>Mon, 10 Feb 2020 00:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/abphage/</guid>
      <description>&lt;h3 id=&#34;abstract&#34;&gt;Abstract&lt;/h3&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Acinetobacter baumannii&lt;/strong&gt;&lt;/em&gt; is one of the most common and troublesome nosocomial pathogens. This project presents the following data on nosocomial &lt;em&gt;A. baumannii&lt;/em&gt; isolates collected from various regions of Russia:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;isolate source data (geographical, clinical data, and basic patient demographics);&lt;/li&gt;
&lt;li&gt;molecular-genetic characteristics of isolates (clonal group, SNP type, sequence type, KL type, presence of acquired carbapenemase genes);&lt;/li&gt;
&lt;li&gt;susceptibility to various antibiotics;&lt;/li&gt;
&lt;li&gt;susceptibility to certain lytic phages.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;bacterial-isolates&#34;&gt;Bacterial isolates&lt;/h3&gt;
&lt;p&gt;The study includes a total of &lt;strong&gt;3,135&lt;/strong&gt; consecutive non-duplicate (one per patient/case of infection) clinical isolates collected between &lt;strong&gt;14 January 2013 and 31 December 2019&lt;/strong&gt; as part of the national surveillance studies from &lt;strong&gt;71 hospitals in 36 cities of Russia&lt;/strong&gt;: : Arkhangelsk, Barnaul, Belgorod, Blagoveshchensk, Chelyabinsk, Irkutsk, Izhevsk, Kazan, Krasnodar, Kurgan, Maykop, Moscow, Murmansk, Naberezhnye Chelny, Nizhny Novgorod, Novosibirsk, Noyabrsk, Omsk, Penza, Perm, Petrozavodsk, Rostov-on-Don, Seversk, Smolensk, St. Petersburg, Tolyatti, Tomsk, Tula, Tver, Tyumen, Ulan-Ude, Vladivostok, Voronezh, Yakutsk, Yekaterinburg, and Yuzhno-Sakhalinsk.&lt;/p&gt;
&lt;h3 id=&#34;antibiotic-susceptibility-testing-ast&#34;&gt;Antibiotic susceptibility testing (AST)&lt;/h3&gt;
&lt;p&gt;Minimum inhibitory concentrations (MICs) of antibiotics were determined by reference broth microdilution method according to ISO 20776-1:2006. The susceptibility categories were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC Clinical Breakpoints v.10.0, 2020 (&lt;a href=&#34;http://www.eucast.org/clinical_breakpoints/&#34;&gt;http://www.eucast.org/clinical_breakpoints/&lt;/a&gt;)&lt;/p&gt;
&lt;h3 id=&#34;phage-susceptibility-testing-pst&#34;&gt;Phage susceptibility testing (PST)&lt;/h3&gt;
&lt;p&gt;Susceptibilities of isolates to selected lytic phages were determined by a modified double-agar-layer method and by spot testing.&lt;/p&gt;
&lt;!-- The results are interpreted as follows: **S** – lysis by phage; **I** – partial lysis; **R** – resistance to phage. PST results are presented together with AST results. --&gt;
&lt;h3 id=&#34;molecular-genetic-subtyping&#34;&gt;Molecular-genetic subtyping&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;All isolates were typed by a single nucleotide polymorphism (SNP)-typing assay based on high-throughput real-time PCR detection of 21informative SNPs in 10 chromosomal loci: &lt;em&gt;gltA, recA, cpn60, gyrB, gdhB, rpoD, fusA, pyrG, rplB,&lt;/em&gt; and &lt;em&gt;rpoB&lt;/em&gt; (&lt;a href=&#34;http://snpt.antibiotic.ru&#34;&gt;http://snpt.antibiotic.ru&lt;/a&gt;:9002/).&lt;/li&gt;
&lt;li&gt;Selected isolates were typed by both the Oxford and Pasteur multilocus sequence typing (MLST) schemes using Sanger or whole genome sequencing (&lt;a href=&#34;https://pubmlst.org/abaumannii/)&#34;&gt;https://pubmlst.org/abaumannii/)&lt;/a&gt;.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;identification-of-capsular-polysaccharide-biosynthesis-gene-clusters-k-loci-kl&#34;&gt;Identification of capsular polysaccharide biosynthesis gene clusters (K-loci, KL)&lt;/h3&gt;
&lt;p&gt;KL types were identified for selected isolates from WGS data using the standard database and nomenclature (&lt;a href=&#34;https://github.com/katholt/Kaptive)&#34;&gt;https://github.com/katholt/Kaptive)&lt;/a&gt;.&lt;/p&gt;
&lt;h3 id=&#34;detection-of-acquired-carbapenemase-genes&#34;&gt;Detection of acquired carbapenemase genes&lt;/h3&gt;
&lt;p&gt;The genes of the most prevalent in &lt;em&gt;Acinetobacter&lt;/em&gt; spp. acquired carbapenemases of molecular class D (OXA-23-, OXA-24/40- and OXA-58-like), class А (GES-2- or GES-5-like), and class B (VIM, IMP and NDM) were determined by means of real-time PCR.&lt;/p&gt;
&lt;h3 id=&#34;study-group&#34;&gt;Study group&lt;/h3&gt;
&lt;p&gt;Roman S. Kozlov, Anastasia V. Popova, Mikhail M. Shneider, Eugene A. Sheck, Mikhail V. Edelstein, Alexey Yu. Kuzmenkov, Andrey V. Romanov, Elvira R. Shaidullina.&lt;/p&gt;
&lt;h3 id=&#34;funding&#34;&gt;Funding&lt;/h3&gt;
&lt;p&gt;This work was conducted with the financial support of the Russian Science Foundation (grant no. 18-15-00403).&lt;/p&gt;
&lt;hr/&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Contact&lt;/h3&gt;
    &lt;h5&gt;Evgenii Shek&lt;/h5&gt;
    &lt;p&gt;Research fellow&lt;/p&gt;
    &lt;p&gt;Institute of Antimicrobial Chemotherapy (IAC),&lt;br&gt;Smolensk State Medical University (SSMU)&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;mailto:evgeniy.sheck@antibiotic.ru&#34; target=&#34;_blank&#34;&gt;evgeniy.sheck@antibiotic.ru&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;iac.png&#34; style=&#34;width: 200px&#34; alt=&#34;Institute of Antimicrobial Chemotherapy (IAC), Smolensk State Medical University (SSMU)&#34;&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
